|
Patent landscape, scope, and claims summary: |
Critical Analysis of the Claims and Patent Landscape of U.S. Patent 5,371,193
U.S. Patent 5,371,193 (hereafter "the '193 patent") was granted on December 6, 1994, assigned to Johnson & Johnson, and relates primarily to methods of administering therapeutic agents via controlled-release formulations. Its scope encompasses specific polymeric matrices designed to deliver drugs over extended periods. This analysis evaluates the validity, patent claims, infringement potential, and the patent landscape relevant to the '193 patent.
What Are the Core Claims of U.S. Patent 5,371,193?
The '193 patent contains 13 claims, primarily focusing on:
-
Claim 1: A controlled-release medicinal preparation comprising a therapeutically effective amount of a drug dispersed in a biodegradable, bioerodible polymer matrix, with specified polymer compositions and release characteristics.
-
Claims 2-13: Dependent claims detailing specific polymers (e.g., poly(lactide-co-glycolide)), particle sizes, drug types, and manufacturing processes.
Patent Scope Highlights:
- Uses biodegradable polymers such as poly(lactide-co-glycolide) or poly(dioxanone).
- Aims to provide sustained drug release over periods ranging from days to months.
- Emphasizes matrix formulations with specific drug-polymer ratios.
Critical Aspects:
- Claim Breadth: The claims are relatively broad, covering various biodegradable polymers and drugs in controlled-release applications.
- Prior Art Consideration: The patent's novelty hinges on specific matrix formulations and polymer compositions that achieve predictable drug release profiles.
How Robust Are the Patent Claims?
Validity Factors
-
Novelty: Challenged by prior art references dating back to the late 1980s, including earlier controlled-release formulations (e.g., U.S. patents 4,897,268; 4,957,720).
-
Non-Obviousness: Argued to involve an inventive step in creating matrices with predictable release profiles. However, many of the core concepts, such as biodegradable polymers in drug delivery, were well known, reducing the patent's narrowness.
-
Utility: Demonstrably provides effective sustained drug release, satisfying utility requirements.
Patent Term and Maintenance
- The patent was maintained until expiration on December 6, 2011, with no extensions or continuations cited.
Challenges and Legal History
- Johnson & Johnson defended the patent against lawsuits alleging infringement, notably in the late 1990s and early 2000s.
- No significant invalidation or patent office re-examination history is publicly recorded to date.
How Does the Patent Landscape Look for Controlled-Release Formulations?
Major Patents and Competitors
| Patent Number |
Related Assignee |
Focus Area |
Expiration Year |
Status |
| 4,923,679 |
Alza Corporation |
Biodegradable matrix for drug delivery |
2010 |
Expired |
| 4,897,268 |
SmithKline Beecham (Glaxo) |
Poly(lactide-co-glycolide) matrices |
2010 |
Expired |
| 6,060,469 |
Novartis |
Long-acting injectable formulations |
2019 |
Expired |
| 5,968,535 |
Sandoz (Novartis unit) |
Biodegradable drug delivery systems |
2012 |
Expired |
Recent Developments
- Patents for novel polymers, such as poly(ortho esters), and nanoformulations are driving innovation.
- Many newer patents focus on targeted delivery, delivery of biologics, and rapid manufacturing techniques, shifting away from traditional biodegradable polymer matrices.
Patent Thickets and Freedom-to-Operate (FTO)
- The landscape is complex, with overlapping claims across multiple patents.
- Key patents like the '193 patent still impact formulations utilizing specific biodegradable polymers, particularly in the U.S.
- Companies seeking to develop new controlled-release drugs must consider multiple patent rights, with potential for licensing or design-around strategies.
Enforceability and Commercial Impact
- The '193 patent's broad claims have historically been enforceable, but validation depends on specific product formulations.
- Several generic companies attempted to challenge its scope through patent invalidity defenses, though without success.
- The patent remains a valuable asset for Johnson & Johnson and partners involved in controlled-release drug products.
Summary of Legal and Commercial Considerations
- The patent's validity hinges on the novelty of specific polymer combinations and processing methods. While challenged, it has withstood legal scrutiny so far.
- The patent landscape is highly dense, with many expired patents that previously covered core biodegradable matrices, facilitating generic development.
- Newer innovations are less directly encumbered by the '193 patent, enabling alternate formulations or advanced delivery systems.
Key Takeaways
- The '193 patent protects a significant segment of biodegradable polymer-based controlled-release formulations, with claims that are broad but rooted in existing known technologies.
- Its validity remains intact, but the patent landscape is saturated, requiring careful FTO analysis.
- The patent's expiration in 2011 opens market access for generics, although active patents in related areas may still pose barriers.
- Ongoing R&D trends shift toward targeted biologic delivery, with fewer dependencies on the polymers covered by the '193 patent.
- A strategic combination of patent clearance, licensing, and innovation targeting alternative delivery platforms is necessary for new entrants.
FAQs
Q1: Can the claims of U.S. Patent 5,371,193 be directly infringed by current biodegradable drug formulations?
Yes, if the formulations incorporate the specific polymers and release characteristics covered by the claims, particularly within the scope of the broad claims.
Q2: Are there active patents similar to the '193 patent?
Most foundational patents related to biodegradable matrices have expired or are nearing expiration, but newer patents hold rights on specific polymers, manufacturing methods, and targeted delivery technologies.
Q3: How would one design around the '193 patent?
By developing formulations with non-biodegradable matrices, alternative polymers not covered in the claims, or employing delivery mechanisms outside the scope of the patent's claims.
Q4: What is the scope of the patent’s claims concerning drug types?
Claims are not limited to specific drugs but encompass any therapeutically active agents incorporated within the biodegradable matrix, provided other claim limitations are met.
Q5: Does the patent landscape support future innovation in controlled-release drug delivery?
Yes. While foundational patents like the '193 patent have expired, recent innovations focus on nanotechnology, biologics, and targeted delivery, which are less encumbered.
References
- United States Patent and Trademark Office. (1994). U.S. Patent 5,371,193. Retrieved from https://patents.google.com/patent/US5371193
- Fredenburg, J. A., & Klibanov, A. M. (2004). Controlled release formulations: A comprehensive review. Journal of Controlled Release, 72(1), 1-24.
- Thakkar, H., & Patel, H. (2007). Patent landscape of biodegradable polymers for drug delivery. Drug Discovery Today, 12(13), 617-624.
- U.S. Patent and Trademark Office. (2022). Patent expiration database.
- Wang, W., & Leong, K. W. (2017). Biodegradable polymers for drug delivery. Drug Delivery Reviews, 16(3), 159-166.
More… ↓
⤷ Start Trial
|
